Siyu Wang

Siyu Wang

Auto-generated profile, based on publicly available information

Siyu Wang

Hospital of Stomatology Sun Yat‐sen University Guangzhou China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 December 2022 in Oral Diseases
Verified
Journal Article
Closed access
SWSiyu Wang
Siyu Wang
LWLi Wang
Li Wang
HLHuan Li
Huan Li
JZJiayu Zhang
Jiayu Zhang
JPJianmin Peng
Jianmin Peng
QHQinchao Hu
Qinchao Hu

22 May 2023 in Oral Diseases
Verified
Journal Article
Closed access
LWLi Wang
Li Wang
SWSiyu Wang
Siyu Wang
JZJiayu Zhang
Jiayu Zhang
JPJianmin Peng
Jianmin Peng
BCBin Cheng
Bin Cheng
QHQinchao Hu
Qinchao Hu

5 December 2023
Verified
Conference Paper
Closed access
GZGuang Zheng
Guang Zheng
FJFeng Jia
Feng Jia
SWSiyu Wang
Siyu Wang
HGHongtao Guo
Hongtao Guo
Exploring the gene expression profile of rheumatoid arthritis (RA) patients with qi-blood-deficiency syndrome may shed light on the pathology of RA patients with qi-blood-deficiency syndrome in traditional Chinese medicine (TCM) towards precision medicine. In this study, GWAS (genome-wide association study), enrichment analysis, and visualizations were deployed on GSE205962 containing samples of RA patients with qi-blood-deficiency syndrome compared with healthy ones. As a result, more than half of differentially expressed genes were weakened/inhibited in RA patients with qi-blood-deficiency syndrome. To be enriched and demonstrated in KEGG RA-associated pathways, these pathways are all weakened and imbalanced with three gene groups: the activated, the inhibited, and the normal group. Besides, enrichment analysis also demonstrated that many signaling pathways are weakened and imbalanced by the development of RA with qi-blood-deficiency syndrome.

23 March 2022 in Zhonghua Zhong Liu Za Zhi [chinese Journal of Oncology]
Verified
Journal Article
Closed access
JZJ Zhang
J Zhang
PYP Yuan
P Yuan
HLH Z Lei
H Z Lei
XLX Y Liu
X Y Liu
XLX Li
X Li
NLN Lyu
N Lyu
Objective: To investigate the expression of programmed death ligand-1 (PD-L1, SP142) and PD-L1 (22C3) in triple-negative breast cancer (TNBC), and analyze their correlation with the clinicopathological factors and prognosis. Methods: The clinicopathologic data of 259 patients with TNBC treated in Cancer Hospital from August 2010 to December 2013 were collected. Whole section of surgical tissue samples were collected to conduct PD-L1 (SP142) and PD-L1 (22C3) immunohistochemical (IHC) staining. The PD-L1 expression in tumor cells and tumor infiltrating immune cells were visually assessed respectively, the relationship between PD-L1 expression and clinicopathologic characterizes were analyzed. Univariable and multivariable Cox proportional hazards regression models were used to test the correlations between PD-L1 expression and disease-free survival (DFS) and overall survival (OS). Results: The positive rates of SP142 (immune cell score, ICs≥1%) and 22C3 (combined positive score, CPS≥1) were 42.1%(109/259) and 41.3%(107/259) in TNBC tissues, respectively, with a total coincidence rate of 82.3%. The Kappa value of positive expression cases was 0.571 and the distribution difference of SP142 and 22C3 positive expression cases was statistically significant (P<0.001). The PD-L1 positive patients were less likely to have vascular invasion (P<0.05), but with higher histological grade and Ki-67 proliferation index (P0.05). Conclusions: The expression of PD-L1 (22C3) is different from that of PD-L1 (SP142) in TNBC, and the two antibodies can't be interchangeable for each other in clinical tests. PD-L1 (SP142) status is an independent prognostic factor of DFS in TNBC. The DFS is significantly prolonged in patients with positive expression of PD-L1 (SP142).